Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Acta Oncologica (Stockholm, Sweden)|November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysisA Kollár, R L Jones, S Stacchiotti, et al.
ESMO Open|December 9, 2022
Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?N S IJzerman, E van Werkhoven, M Mohammadi, et al.
ESMO Open|June 2, 2022
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRCS Kopetz, A Grothey, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Clinical Pharmacology and Therapeutics|February 26, 2014
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662M H M Diekstra, H J Klümpen, M P J K Lolkema, et al.
ESMO Open|February 15, 2025
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancerS M Buijs, M I Mohmaed Ali, E Oomen-de Hoop, et al.
ESMO Open|September 12, 2021
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC studyE Younger, R L Jones, D den Hollander, et al.
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapiesG A Cirkel, F Weeber, S Bins, et al.
ESMO Open|December 4, 2022
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnosticsL J Schipper, K G Samsom, P Snaebjornsson, et al.
Pageof 5